Docosahexaenoic acid inhibition of inflammation is partially via cross-talk between Nrf2/heme oxygenase 1 and IKK/NF-κB pathways

J Nutr Biochem. 2013 Jan;24(1):204-12. doi: 10.1016/j.jnutbio.2012.05.003. Epub 2012 Aug 15.

Abstract

We examined the underlying mechanisms involved in n-3 docosahexaenoic acid (DHA) inhibition of inflammation in EA.hy926 cells. The present results demonstrated that pretreatment with DHA (50 and 100 μM) inhibited tumor necrosis factor-alpha (TNF-α)-induced intercellular adhesion molecule 1 (ICAM-1) protein, mRNA expression and promoter activity. In addition, TNF-α-stimulated inhibitory kappa B (IκB) kinase (IKK) phosphorylation, IκB phosphorylation and degradation, p65 nuclear translocation, and nuclear factor-κB (NF-κB) and DNA binding activity were attenuated by pretreatment with DHA. DHA triggered early-stage and transient reactive oxygen species (ROS) generation and significantly increased the protein expression of heme oxygenase 1 (HO-1), induced nuclear factor erythroid 2-related factor 2 (Nrf2) translocation to the nucleus and up-regulated antioxidant response element (ARE)-luciferase reporter activity. Moreover, DHA inhibited Nrf2 ubiquitination and proteasome activity. DHA activated Akt, p38 and ERK1/2 phosphorylation, and specific inhibitors of respective pathways attenuated DHA-induced Nrf2 nuclear translocation and HO-1 expression. Transfection with HO-1 siRNA knocked down HO-1 expression and partially reversed the DHA-mediated inhibition of TNF-α-induced p65 nuclear translocation and ICAM-1 expression. Importantly, we show for the first time that HO-1 plays a down-regulatory role in NF-κB nuclear translocation, and inhibition of Nrf2 ubiquitination and proteasome activity are involved in increased cellular Nrf2 level by DHA. In this study, we show that HO-1 plays a down-regulatory role in NF-κB nuclear translocation and that the protective effect of DHA against inflammation is partially via up-regulation of Nrf2-mediated HO-1 expression and inhibition of IKK/NF-κB signaling pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Cell Adhesion / drug effects
  • Cell Line
  • Docosahexaenoic Acids / pharmacology*
  • Endothelium, Vascular / cytology
  • Gene Knockdown Techniques
  • HL-60 Cells
  • Heme Oxygenase-1 / genetics
  • Heme Oxygenase-1 / metabolism*
  • Humans
  • I-kappa B Kinase / metabolism*
  • Inflammation / chemically induced
  • Inflammation / drug therapy*
  • Inflammation / metabolism
  • Intercellular Adhesion Molecule-1 / genetics
  • Intercellular Adhesion Molecule-1 / metabolism
  • NF-E2-Related Factor 2 / metabolism*
  • NF-kappa B / metabolism*
  • Promoter Regions, Genetic
  • Protein Transport / drug effects
  • RNA, Small Interfering
  • Reactive Oxygen Species / metabolism
  • Signal Transduction / drug effects
  • Tumor Necrosis Factor-alpha / adverse effects
  • Up-Regulation / drug effects

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • NF-E2-Related Factor 2
  • NF-kappa B
  • NFE2L2 protein, human
  • RNA, Small Interfering
  • Reactive Oxygen Species
  • Tumor Necrosis Factor-alpha
  • Intercellular Adhesion Molecule-1
  • Docosahexaenoic Acids
  • HMOX1 protein, human
  • Heme Oxygenase-1
  • I-kappa B Kinase